Related Experiment Video
Updated: Jul 17, 2026
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
Evaluation of cancer chemopreventive agents using clones derived from a human prostate cancer cell line
Jeffrey H Ware1, Zhaozong Zhou, Levy Kopelovich
1Department of Radiation Oncology, Division of Oncology Research, University of Pennsylvania School of Medicine, 3620 Hamilton Walk, Philadelphia, PA 19104-6072, USA. jhware@mail.med.upenn.edu
Background:
The successful use of clonal selection through fluctuation analysis of human cancer cells as a means for studying tumor progression has been previously reported.
Materials And Methods:
Three clones derived from a parental population of human prostate cancer (LNCaP) cells were selected based on proliferation, hormone sensitivity and anchorage-independent growth. The effects of five potential cancer preventive agents were evaluated using cell proliferation, anchorage-independent growth and apoptosis as end-points.
Results:
Clone 21 cells, which represent a presumptive normal phenotype, were generally more sensitive than Clone 17 and Clone 6 cells, which represent a more malignant phenotype, to fluasterone, 7beta-HF, L-selenomethionine and troglitazone in assays for proliferation and/or apoptosis.
Conclusion:
The results confirm the efficacy of the above agents as cancer chemopreventive agents and support our contention that clonal selection of established human cancer cells provides a model to study the efficacy of chemopreventive agents.
